DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Sentry Investment Management LLC

Sentry Investment Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 131.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,340 shares of the medical device company’s stock after buying an additional 2,466 shares during the quarter. Sentry Investment Management LLC’s holdings in DexCom were worth $337,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter valued at $25,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the 4th quarter valued at about $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $54,000. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the third quarter worth about $57,000. Finally, Rothschild Investment LLC grew its position in DexCom by 250.5% during the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after buying an additional 536 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on DXCM shares. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company lifted their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Citigroup upped their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Stock Performance

NASDAQ:DXCM opened at $88.32 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $34.51 billion, a PE ratio of 61.76, a P/E/G ratio of 2.30 and a beta of 1.14. The firm has a 50 day simple moving average of $83.99 and a 200-day simple moving average of $76.38. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.